Adaptimmune Therapeutics (ADAP) Prices 11.25M IPO at $17/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Adaptimmune Therapeutics (ADAP) IPO Opens Up 13%
May 6, 2015 10:45 AM EDTToday's IPO for Adaptimmune Therapeutics plc (Nasdaq: ADAP) opened for trading at $19.25 after pricing 11,250,000 American Depositary Shares (ADSs) at a price to the public of $17.00 per ADS.
BofA Merrill Lynch, Cowen and Company and Leerink Partners LLC are acting as joint book-running... More
